Engineering Related Topics 
Drug Discovery World
DECEMBER 19, 2023
The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Immusoft is advancing the world’s first engineered B cell therapy, which may have significant impact for patients with this rare disease and potentially many others.
Drug Discovery World
MAY 9, 2024
Mekonos, a company working towards cell engineering on a chip, has entered into a partnership agreement with Accelerated Bio to codevelop a new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 24, 2023
The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The post Successful clinical trial for re-engineered Covid vaccine appeared first on Drug Discovery World (DDW).
Drug Discovery World
APRIL 9, 2024
A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.
Drug Discovery World
MAY 4, 2023
Adaptyv Bio, a Swiss/US technology company that develops infrastructure and tools for protein designers to engineer better proteins, has built a protein engineering foundry that it says will “pave the way” for protein designers to develop new medicines, novel enzymes and sustainable materials. And imagine each execution costs $1000.
Drug Discovery World
MAY 11, 2023
The first DNA synthesised using Evonetix’s semiconductor chip technology has been delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The DNA was delivered to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge.
Drug Discovery World
AUGUST 31, 2023
“The discovery and characterisation of these novel scaffolds proprietary to Evox provides a new platform for exosome-based engineering and represents a five to ten-fold improvement over previously identified exosome scaffolds,” said Dr Antonin de Fougerolles, Chief Executive Officer of Evox. The post Advances continue for Evox’ exosome engineering (..)
Expert insights. Personalized for you.
284 
Let's personalize your content